These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38798250)

  • 21. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
    Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal conditions of LDR to protect the kidney from diabetes: exposure to 12.5 mGy X-rays for 8 weeks efficiently protects the kidney from diabetes.
    Cheng J; Li F; Cui J; Guo W; Li C; Li W; Wang G; Xing X; Gao Y; Ge Y; Wang G; Cai L
    Life Sci; 2014 May; 103(1):49-58. PubMed ID: 24631139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure.
    Liu YD; Tang G; Qian F; Liu L; Huang JR; Tang FR
    Curr Med Chem; 2021; 28(10):1970-1986. PubMed ID: 32520676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
    Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
    Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
    Ferini-Strambi L; Salsone M
    J Neurol; 2021 Feb; 268(2):409-419. PubMed ID: 32696341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
    Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
    Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
    Ostapiuk A; Urbanska EM
    CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-Dose Radiation Reduces Doxorubicin-Induced Myocardial Injury Through Mitochondrial Pathways.
    Zhao D; Jiang X; Meng X; Liu D; Du Y; Zhao L; Jiang H
    Dose Response; 2023; 21(1):15593258231155789. PubMed ID: 36798636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of Panax ginseng and its constituents, ginsenosides and gintonin, in neurological and neurodegenerative disorders: a patent review.
    Rajabian A; Rameshrad M; Hosseinzadeh H
    Expert Opin Ther Pat; 2019 Jan; 29(1):55-72. PubMed ID: 30513224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioprotective effect of melatonin against radiotherapy-induced cerebral cortex and cerebellum damage in rat.
    Aras S; Efendioğlu M; Wulamujiang A; Ozkanli SS; Keleş MS; Tanzer İO
    Int J Radiat Biol; 2021; 97(3):348-355. PubMed ID: 33320758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term LDR exposure may induce cognitive impairments: A possible association through targeting gut microbiota-gut-brain axis.
    Guo P; Lei M; Hu S; Xu Z; Zhou Y; Zhou P; Huang R
    Ecotoxicol Environ Saf; 2023 Jan; 249():114351. PubMed ID: 36508818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The initial results on the radiobiological comparability of continuous LDR irradiation and PDR irradiation using a guinea pig skin animal model].
    Brock A; Prager W; Pohlmann S; Friedrich K
    Strahlenther Onkol; 1995 Nov; 171(11):641-5. PubMed ID: 7502227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNAi applications in therapy development for neurodegenerative disease.
    Maxwell MM
    Curr Pharm Des; 2009; 15(34):3977-91. PubMed ID: 19751205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose-rate ionizing radiation affects innate immunity protein IFITM3 in a mouse model of Alzheimer's disease.
    Son Y; Lee CG; Kim JS; Lee HJ
    Int J Radiat Biol; 2023; 99(11):1649-1659. PubMed ID: 37162420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mice Exposed to Combined Chronic Low-Dose Irradiation and Modeled Microgravity Develop Long-Term Neurological Sequelae.
    Overbey EG; Paul AM; da Silveira WA; Tahimic CGT; Reinsch SS; Szewczyk N; Stanbouly S; Wang C; Galazka JM; Mao XW
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
    Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
    Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases.
    Duarte-Neves J; Pereira de Almeida L; Cavadas C
    Neurobiol Dis; 2016 Nov; 95():210-24. PubMed ID: 27461050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.